Balakrishnan Rengasamy, Kim Yon-Suk, Kang Shin-Il, Choi Dong-Kug
Department of Applied Life Sciences, Graduate School, BK21 Program, Konkuk University, Chungju 27478, South Korea; Department of Biotechnology, College of Biomedical and Health Science, Research Institute of Inflammatory Disease (RID), Konkuk University, Chungju 27478, South Korea.
Department of Biotechnology, College of Biomedical and Health Science, Research Institute of Inflammatory Disease (RID), Konkuk University, Chungju 27478, South Korea.
Biomed Pharmacother. 2025 Aug;189:118295. doi: 10.1016/j.biopha.2025.118295. Epub 2025 Jun 27.
Alzheimer's disease (AD) is a progressive neurodegenerative condition, with mild cognitive impairment (MCI) often presenting as an early symptom. Patients with MCI are more likely to experience subsequent long-term cognitive impairments and memory dysfunction. Currently, there are no effective therapeutic agents available for the clinical treatment of AD due to its highly complex pathogenesis. We investigated the neuroprotective and anti-inflammatory effects of green oat cognitaven® in vitro, using lipopolysaccharide (LPS)-stimulated BV-2 microglial cells, and in vivo, using a scopolamine-injected C57BL/6 J amnesic mouse model. The mice were orally administered green oat cognitaven® (90, 180, and 270 mg/kg/b.w.) for 14 days and injected intraperitoneally with scopolamine (1 mg/kg/b.w.) for 14 days. In vitro, green oat cognitaven® exhibited multiple actions in LPS-stimulated BV-2 microglial cells, including strong inhibition of NO release, significantly reduced inflammatory responses, and anti-inflammatory effects. Green oat cognitaven® also demonstrated vigorous anti-neuroinflammatory activity in these cells, inhibiting the activation and phosphorylation of the NF-κB/MAPK signaling pathway. In vivo, the oral administration of green oat cognitaven® in scopolamine-induced amnesic mice produced significant anti-amnesic effects-preventing spatial learning and memory impairments-and demonstrated potent neuroprotective activity through the upregulation of associated biomarkers, including p-CREB and BDNF protein expression. Further experiments showed that green oat cognitaven® upregulates Nrf2/HO-1 expression and mitigates neuroinflammation by inhibiting NF-κB and MAPK signaling. Overall, our study indicated that green oat cognitaven® is a functional dietary component and explores its therapeutic potential to support the treatment and management of AD-associated MCI.
阿尔茨海默病（AD）是一种进行性神经退行性疾病，轻度认知障碍（MCI）常作为早期症状出现。MCI患者更有可能经历随后的长期认知障碍和记忆功能障碍。目前，由于AD的发病机制高度复杂，尚无有效的治疗药物可用于临床治疗。我们在体外使用脂多糖（LPS）刺激的BV-2小胶质细胞，在体内使用东莨菪碱注射的C57BL/6J遗忘小鼠模型，研究了绿色燕麦cognitaven®的神经保护和抗炎作用。小鼠口服绿色燕麦cognitaven®（90、180和270mg/kg体重），持续14天，并腹腔注射东莨菪碱（1mg/kg体重），持续14天。在体外，绿色燕麦cognitaven®在LPS刺激的BV-2小胶质细胞中表现出多种作用，包括强烈抑制NO释放、显著降低炎症反应和抗炎作用。绿色燕麦cognitaven®在这些细胞中还表现出强烈的抗神经炎症活性，抑制NF-κB/MAPK信号通路的激活和磷酸化。在体内，给东莨菪碱诱导的遗忘小鼠口服绿色燕麦cognitaven®产生了显著的抗遗忘作用——预防空间学习和记忆障碍——并通过上调相关生物标志物（包括p-CREB和BDNF蛋白表达）表现出强大的神经保护活性。进一步的实验表明，绿色燕麦cognitaven®上调Nrf2/HO-1表达，并通过抑制NF-κB和MAPK信号减轻神经炎症。总体而言，我们的研究表明绿色燕麦cognitaven®是一种功能性饮食成分，并探索了其支持治疗和管理AD相关MCI的治疗潜力。
